Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HALO Stock Forecast 2026-2027
$69.50
Current Price
$8.24B
Market Cap
Buy 6
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to HALO Price Targets
+38.1%
To High Target of $96.00
+28.1%
To Median Target of $89.00
-18.0%
To Low Target of $57.00
HALO Price Momentum
-1.7%
1 Week Change
+3.5%
1 Month Change
+28.8%
1 Year Change
+3.3%
Year-to-Date Change
-15.5%
From 52W High of $82.22
+36.1%
From 52W Low of $51.06
📊 TOP ANALYST CALLS
Did HALO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Halozyme is one of their latest high-conviction picks.
Latest HALO Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, HALO has a bullish consensus with a median price target of $89.00 (ranging from $57.00 to $96.00). The overall analyst rating is Buy (7.6/10). Currently trading at $69.50, the median forecast implies a 28.1% upside. This outlook is supported by 6 Buy, 3 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HALO Analyst Ratings
6
Buy
3
Hold
1
Sell
HALO Price Target Range
Low
$57.00
Average
$89.00
High
$96.00
Current: $69.50
Latest HALO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HALO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2026 | Morgan Stanley | Vikram Purohit | Overweight | Maintains | $93.00 |
| Apr 29, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 19, 2026 | Benchmark | Buy | Maintains | $N/A | |
| Feb 19, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jan 8, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Dec 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 18, 2025 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Nov 4, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Oct 27, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Oct 20, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Oct 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 14, 2025 | Leerink Partners | Market Perform | Upgrade | $N/A | |
| Oct 2, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 24, 2025 | Benchmark | Buy | Maintains | $N/A | |
| Sep 22, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 18, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Aug 7, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Aug 6, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Aug 6, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Halozyme Therapeutics Inc. (HALO) Competitors
The following stocks are similar to Halozyme based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Halozyme Therapeutics Inc. (HALO) Financial Data
Halozyme Therapeutics Inc. has a market capitalization of $8.24B with a P/E ratio of 24.8x. The company generates $1.51B in trailing twelve-month revenue with a 23.1% profit margin.
Revenue growth is +42.2% quarter-over-quarter, while maintaining an operating margin of +49.0% and return on equity of +99.4%.
Valuation Metrics
Market Cap
$8.24B
Enterprise Value
$10.22B
P/E Ratio
24.8x
PEG Ratio
0.8x
Price/Sales
5.6x
Growth & Margins
Revenue Growth (YoY)
+42.2%
Gross Margin
+79.0%
Operating Margin
+49.0%
Net Margin
+23.1%
EPS Growth
+27.1%
Financial Health
Cash/Price Ratio
+3.9%
Current Ratio
2.8x
Debt/Equity
991.2x
ROE
+99.4%
ROA
+22.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Halozyme Therapeutics Inc. (HALO) Business Model
About Halozyme Therapeutics Inc.
What They Do
Develops drug delivery technologies and enzymes.
Business Model
The company generates revenue by licensing its ENHANZE drug delivery technology to pharmaceutical partners for co-formulation of treatments, primarily in oncology and endocrinology. Additionally, it commercializes its proprietary products like Hylenex and XYOSTED to enhance drug delivery methods, thereby improving patient outcomes.
Additional Information
Founded in 1998 and based in San Diego, California, Halozyme has expanded its capabilities through strategic acquisitions, such as Elektrofi, to enhance its product offerings. The company operates mainly in the U.S. but has a global presence, collaborating with major biopharmaceutical firms to innovate patient-friendly therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
423
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Country
United States
IPO Year
2004
Website
halozyme.comHalozyme Therapeutics Inc. (HALO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 10, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Halozyme Therapeutics (HALO) reported earnings 30 days ago; investors should monitor upcoming developments for potential stock movements.
Why It Matters
Upcoming earnings reports can significantly impact stock prices, indicating potential growth or decline. Investors will assess Halozyme's performance for future opportunities or risks.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors should monitor HALO stock due to recent significant activity in the options market.
Why It Matters
Movements in the options market can indicate shifts in investor sentiment or expectations for HALO stock, potentially signaling upcoming price volatility or opportunities.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Halozyme Therapeutics: Royalty King
26 days ago
Quick Summary
Halozyme Therapeutics reported strong Q1 2026 earnings with a double beat, reaffirmed guidance, and announced a $1 billion share repurchase program. It trades at a discount despite >75% gross margins.
Why It Matters
Halozyme's strong earnings, reaffirmed guidance, and a $1 billion buyback signal robust financial health and potential for stock appreciation, despite undervaluation relative to peers.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
HALO exceeded Q1 earnings estimates, reporting a 42% year-over-year revenue increase driven by royalties from partner drugs and strong product sales.
Why It Matters
HALO's Q1 earnings beat indicates robust financial health and growth potential, driven by increased royalty revenues and product sales, which can boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Halozyme Therapeutics (NASDAQ: HALO) reported a significant increase in Q1 2026 revenue and earnings, fueled by growth in ENHANZE royalties, and announced a $1 billion share repurchase program.
Why It Matters
Halozyme's revenue and earnings growth signals strong business performance, boosting investor confidence. The $1 billion share repurchase may enhance shareholder value by reducing supply and increasing earnings per share.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Halozyme Therapeutics, Inc. (HALO) held its Q1 2026 earnings call, discussing financial performance and company updates. For detailed figures and insights, refer to the full transcript.
Why It Matters
Halozyme's Q1 2026 earnings call provides insights into financial performance, growth potential, and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About HALO Stock
What is Halozyme Therapeutics Inc.'s (HALO) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Halozyme Therapeutics Inc. (HALO) has a median price target of $89.00. The highest price target is $96.00 and the lowest is $57.00.
Is HALO stock a good investment in 2026?
According to current analyst ratings, HALO has 6 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $69.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HALO stock?
Wall Street analysts predict HALO stock could reach $89.00 in the next 12 months. This represents a 28.1% increase from the current price of $69.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Halozyme Therapeutics Inc.'s business model?
The company generates revenue by licensing its ENHANZE drug delivery technology to pharmaceutical partners for co-formulation of treatments, primarily in oncology and endocrinology. Additionally, it commercializes its proprietary products like Hylenex and XYOSTED to enhance drug delivery methods, thereby improving patient outcomes.
What is the highest forecasted price for HALO Halozyme Therapeutics Inc.?
The highest price target for HALO is $96.00 from at , which represents a 38.1% increase from the current price of $69.50.
What is the lowest forecasted price for HALO Halozyme Therapeutics Inc.?
The lowest price target for HALO is $57.00 from at , which represents a -18.0% decrease from the current price of $69.50.
What is the overall HALO consensus from analysts for Halozyme Therapeutics Inc.?
The overall analyst consensus for HALO is bullish. Out of 3 Wall Street analysts, 6 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $89.00.
How accurate are HALO stock price projections?
Stock price projections, including those for Halozyme Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 2:58 AM UTC